Tiong IS, Hiwase DK, Abro E, Bajel A, et al. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). J Clin Oncol 2024;42:2161-2173.
PMID: 38427924